Denali Capital Acquisition Corp. Unit
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch DNQUF and buy or sell other stocks, ETFs, and their options commission-free!About DNQUF
Semnur Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative non-opioid pain management products for the treatment of acute and chronic pain. Its lead product candidate, SP-102, is a non-opioid novel injectable corticosteroid gel formulation for patients with moderate to severe lumbosacral radicular pain.
CEOJaisim Shah, MBA
CEOJaisim Shah, MBA
Employees2
Employees2
HeadquartersPalo Alto, California
HeadquartersPalo Alto, California
Founded
Founded
Employees2
Employees2
DNQUF Key Statistics
Market cap2.98B
Market cap2.98B
Price-Earnings ratio-27.93
Price-Earnings ratio-27.93
Dividend yield—
Dividend yield—
Average volume—
Average volume—
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$12.99
52 Week high$12.99
52 Week low$10.42
52 Week low$10.42
Stock Snapshot
The current Denali Capital Acquisition Corp. Unit(DNQUF) stock price is $12.99, with a market capitalization of 2.98B. The stock trades at a price-to-earnings (P/E) ratio of -27.93.
During the trading day, Denali Capital Acquisition Corp. Unit(DNQUF) stock saw an opening price of —, a peak of —, and a bottom of —.
Trading volume for Denali Capital Acquisition Corp. Unit(DNQUF) stock has reached 0.
The stock's 52-week range extends from a low of $10.42 to a high of $12.99.
The stock's 52-week range extends from a low of $10.42 to a high of $12.99.